文献速递角膜与眼表疾病白内障与屈光手术

药物递送系统治疗眼前节炎症的临床应用综述

A review of the clinical applications of drug delivery systems for the treatment of ocular anterior segment inflammation.
PubMed 文献 · Br J Ophthalmol · 2020-10-30

本文综述了用于治疗眼前节炎症(见于白内障术后及非感染性前葡萄膜炎)的药物递送系统(DDS)。局部激素滴眼液是主要治疗手段,但存在生物利用度低、依从性差等缺点。综述列举并总结了已获FDA批准的DDS产品及临床试验中的新系统,指出纳米颗粒和眼离子导入有望成为替代局部滴眼液的新选择。

要点

  • 局部激素滴眼液是眼前节炎症的主要治疗,但生物利用度低且依从性差。
  • Dextenza、INVELTYS、Dexycu和Bromsite是已获FDA批准的DDS产品。
  • 纳米颗粒和眼离子导入是下一波有望替代滴眼液的DDS。

核心结论

  • 能提高生物利用度并靶向炎症组织的DDS有望替代每日滴眼液成为眼前节炎症治疗的金标准。

研究设计与样本

  • 综述文献,聚焦已商业化的DDS产品及临床试验中的DDS,未报告检索范围与样本量。

主要发现

  • Dextenza、INVELTYS、Dexycu和Bromsite在临床试验中取得成功并获FDA批准。
  • 纳米颗粒和眼离子导入构成下一波DDS,有潜力替代局部激素滴眼液。

临床怎么用

  • 临床可关注已获FDA批准的DDS产品用于眼前节炎症治疗。
  • 纳米颗粒和眼离子导入等新兴DDS可能解决生物利用度低和依从性差的问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ocular anterior segment inflammation is a medical problem that is seen in cases of cataract surgery and non-infectious anterior uveitis. Inadequately treated anterior segment inflammation can lead to sight-threatening conditions such as corneal oedema, glaucoma and cystoid macular oedema. The mainstay of treatment for anterior segment inflammation is topical steroid eye-drops. However, several drawbacks limit the critical value of this treatment, including low bioavailability, poor patient compliance, relatively difficult administration manner and risk of blurring of vision and ocular irritation. A drug delivery system (DDS) that can provide increased bioavailability and sustained delivery while being specifically targeted towards inflamed ocular tissue can potentially replace daily eye-drops as the gold standard for management of anterior segment inflammation. The various DDS for anti-inflammatory drugs for the treatment of anterior segment inflammation are listed and summarised in this review, with a focus on commercially available products and those in clinical trials. Dextenza, INVELTYS, Dexycu and Bromsite are examples of DDS that have enjoyed success in clinical trials leading to FDA approval. Nanoparticles and ocular iontophoresis form the next wave of DDS that have the potential to replace topical steroids eye-drops as the treatment of choice for anterior segment inflammation. With the current relentless pace of ophthalmic drug delivery research, the pursuit of a new standard of treatment that eliminates the problems of low bioavailability and patient compliance may soon be realised.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Wong CW, Metselaar JM, Storm G, et al. A review of the clinical applications of drug delivery systems for the treatment of ocular anterior segment inflammation. Br J Ophthalmol. 2020. PMID: 33127826. doi:10.1136/bjophthalmol-2020-315911

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。